Viatris Inc.

Viatris Inc. is a global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania, with additional global centers in Pittsburgh, Shanghai, and Hyderabad. Formed on November 16, 2020, through the merger of Mylan and Upjohn, a legacy division of Pfizer, its mission is to empower people worldwide to live healthier at every stage of life. This mission is rooted in expanding access to medicines, innovating to meet patient needs, and serving as a trusted partner for the global healthcare community.

The company offers a diverse portfolio of medicines, including branded drugs, generics (both branded and complex), biosimilars, over-the-counter products, and active pharmaceutical ingredients. Viatris products address a broad range of therapeutic areas such as cardiovascular, infectious disease, oncology, immunology, CNS and anesthesia, women's healthcare, diabetes and metabolism, gastroenterology, respiratory and allergy, and dermatology. Serving patients across various demographics, healthcare providers, pharmacies, and governments, Viatris operates in over 165 countries, focusing on both developed and emerging markets.

Scott A. Smith has served as CEO since April 2023. Viatris positions itself as a leader in global healthcare access, aiming to bridge the gap between generic and branded pharmaceutical offerings while advancing sustainable operations. The company is strategically expanding its pipeline, with a focus on complex generics, biosimilars, and specialty areas like ophthalmology, dermatology, and gastroenterology. Recent developments include presenting data on an investigational low-dose estrogen combined hormonal contraceptive weekly patch in May 2026, with an FDA target action date of July 30, 2026. In March 2026, Japan approved Effexor SR capsules for generalized anxiety disorder. The company also launched Inpefa® (Sotagliflozin) for heart failure in January 2026. Notably, Viatris disclosed an FDA warning letter and import alert concerning its Indore, India facility in late December 2024, impacting 11 products. This followed strategic divestitures in October 2023 of its OTC, women's healthcare, and India-based API businesses, totaling approximately $3.6 billion.